Tuberculous meningitis is a life threatening form of tuberculosis and the most common form of central nervous system tuberculosis. The condition is a serious cause of morbidity and mortality in developing nations, but is rare in technically advanced countries. This probably reflects the global epidemiology of tuberculosis, for out of an estimated 8 million new cases annually 7-6 million (95%) occur in the third world.' In England and Wales in 1983 the rate of tuberculous meningitis for white patients was 0 1/ 100 000, yet was 40 times higher (a rate of 4/100 000) in patients of Indian subcontinent ethnic origin.2 The total number of cases notified in England and Wales has remained below 100 since 1982; there were 81 notifications in 1990 (JM Watson and K Fern, personal communication), predominantly in adults.
Tuberculosis has emerged as an important clinical problem in patients with AIDS and its related complex, 34 and extrapulmonary disease is particularly common. Central nervous system tuberculosis is an important manifestation. In one review of 420 patients in the United States with AIDS or the AIDS related complex 52 developed tuberculosis, 10 (25) 23 (32) 12 (17) Total 199 123 (62) 12 (6) 25 (13) 26 (13) 13 (6) to have influenced the treatment outcome. (Ellard et al, in preparation) . Further, two hour rifampicin concentrations showed a positive correlation with protein and a negative correlation with glucose in the cerebrospinal fluid and at 5 hours rifampicin concentrations correlated with high cerebrospinal fluid white cell count, suggesting that the penetration of rifampicin into the cerebrospinal fluid may be related to the degree of meningeal inflammation. 35 The relatively low concentrations of rifampicin in the cerebrospinal fluid are likely to be similar to the concentrations found in cavity walls in pulmonary tuberculosis, a condition where the contribution of rifampicin has been shown to be critical for the success of short course regimens. Although the contribution of rifampicin is unproved, possibly rifampicin is almost as active in tuberculous meningitis as in pulmonary tuberculosis.
Pyrazinamide has a sterilising effect on tubercle bacilli in an acid environment, and its incorporation in short course chemotherapy for pulmonary tuberculosis has significantly reduced relapse rates.2737 Oral doses of the drug are rapidly absorbed and peak serum concentrations are achieved within two hours, being proportional to the dose given.38 It penetrates readily into the cerebrospinal fluid. Although evidence for this conclusion was for many years based on studies in a single patient,32 recently those results have been confirmed by several extensive studies. Thus a large study of 28 Chinese patients with tuberculous meningitis39 found cerebrospinal fluid:serum ratios of pyrazinamide of 0 74, 1-15, and 1 09 at 2, 5, and 8 hours respectively after oral dosages of 34-41 mg/kg. This excellent penetration was not influenced by the stage of disease, the presence or absence of active disease, the concomitant use of steroids, the duration of antituberculosis treatment, administration of either ethambutol or streptomycin, or the age or sex of the patient. These findings have been confirmed in reports from South Africa40 and Thailand.364' These concentrations were above those required for the inhibition of growth After the initial period in hospital daily supervised treatment is continued on an outpatient basis if possible. In contrast to studies on pulmonary tuberculosis, there are no data on the efficacy ofthrice weekly regimens in meningitis.
Corticosteroids are prescribed routinely for patients in stages 2 and 3. Dexamethasone is given in a dose of 0-2 mg/kg for one to three weeks initially, being tailed down to 0-1 mg/kg and continued for a total of two to three months, depending on clinical progress.
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